Anthem Biosciences bets ₹1,200 cr on GLP-1 plant expansion

Anthem Biosciences just posted record quarterly revenue of ₹611 crore. It is not slowing down.

Management committed ₹1,200 crore to expand its Unit 4 facility, which aims to double custom synthesis capacity by March 2028. The strategy hinges on the Indian GLP-1 market, where the company expects to launch its active ingredient within the next 6-8 months, pending necessary formulator approvals. Beyond this immediate push, the pipeline has reached 10 Phase 3 molecules. While management held back on explicit FY27 guidance, they are targeting long-term growth of 20% across key profit and revenue metrics. Anthem is moving fast; the next test is whether those regulatory approvals arrive on the expected 6-8 month schedule. With a major capex cycle underway, the company has clearly pivoted toward scaling its late-stage pharmaceutical manufacturing footprint to capture share in the high-demand, high-complexity drug market.